Q Genetics secured investment from K-Ground Partners' IP Fund, giving impetus to its new drug development endeavors. Subsequent to the completion of its Phase 1 trial, t ...

August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new ...

Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click ...

Since becoming only the second Alzheimer's-modifying drug to gain American Federal Drug Administration approval in 2023, ...

Adolescents with alopecia areata achieve hair regrowth with 80% or more of scalp coverage while taking the Janus kinase inhibitor baricitinib, a phase 3 study finds.

The SMA gene therapy candidate OAV101 IT, a version of Zolgensma, can be safely given to previously treated patients, per new trial data.

Fast Company's annual list of the World's Most Innovative Companies spotlights organizations across various industries that are driving meaningful change through groundbreaking ideas and ...

Data from two studies suggest that a once-daily combination therapy of doravirine and islatravir was noninferior to current, ...

Newly released data from the phase 3 STOP-HS clinical trial program reveal positive results in hidradenitis suppurativa from ...

Learn more about whether ACADIA Pharmaceuticals Inc. or Merus N.V. is a better investment based on AAII's A+ Investor grades, ...

Povorcitinib is an oral Janus kinase 1 selective inhibitor that works to reduce the overactive inflammatory signaling pathway seen in HS.

Shares of Incyte sank Monday, making it the biggest decliner in the S&P 500 after the release of its latest clinical trial.